IMPACT - Targeted prostate cancer screening - Peter MacCallum Cancer Centre

This is an international prostate cancer screening study for men with inherited BRCA and mismatch repair (MMR) gene mutations who are at increased risk of prostate cancer. Peter Mac coordinates the Australian axis of the study. Australia has recruited one fifth of the entire worldwide cohort to date with Peter Mac the site of the greatest number of Australian recruits.

The IMPACT study will determine how best to screen men with these mutations for prostate cancer and to find new screening tools for prostate cancer in this high-risk group.

Principal investigator

Professor Paul James

Contact details

Ms Joanne McKinley

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 03 8559 6195

Project group

Familial Cancer Research Centre

Project status

Active

Publications and Presentations

Bancroft EK, Page EC et al. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncol. 2021 Nov;22(11):1618-1631. doi: 10.1016/S1470-2045(21)00522-2. Epub 2021 Oct 19. PMID: 34678156; PMCID: PMC8576477.
Page EC, Bancroft EK et al. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76(6):831-842.
Risbridger GP, Taylor RA, Clouston D, Sliwinskid A, Thorne H, Hunter S, Li J, Mitchell G, Murphy D, Frydenberg M, Pook D, Pedersen J, Toivanena J, Wanga H, Papargirisa M, Lawrence MG, Bolton DM. Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis. European Urology. 2014 Aug 22. 10.1016
Killick E, Tymrakiewicz M, Cieza-Borrella C, Smith P, Thompson DJ, Pooley KA, Easton DF, Bancroft E, Page E, Leongamornlert D; IMPACT collaborators, Kote-Jarai Z, Eeles RA. Telomere length shows no association with BRCA1 and BRCA2 mutation status. PLoS One. 2014 Jan 29;9(1):e86659.
Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU International. 2011 Jan;107(1):28-39
Bancroft EK, Page EC, et al., The IMPACT Collaboratorsy, Moss, Eeles RA. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. Eur Urol. 2014 Sep;66(3):489-99
Cremers RG, Eeles RA, Bancroft EK, Ringelberg-Borsboom J, Vasen HF, Van Asperen CJ; IMPACT Steering Committee, Schalken JA, Verhaegh GW, Kiemeney LA. The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. Urol Oncol. 2015 May;33(5):202.e19-28. doi: 10.1016/j.urolonc.2015.01.018. Epub 2015 Mar